Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513322 | 1.00 | DRD3 (0.46) | DRD3HSD11B1DRD2 | |
| SCHEMBL4511951 | 1.00 | DRD3 (0.46) | DRD3HSD11B1DRD2 | |
| SCHEMBL25398545 | 0.88 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL4496839 | 0.77 | HSD11B1 (0.70) | HSD11B1 | |
| SCHEMBL4496840 | 0.77 | HSD11B1 (0.70) | HSD11B1 | |
| SCHEMBL14161599 | 0.73 | DRD3 (0.53) | DRD3DRD2 | |
| Hydrochloric Acid SCHEMBL11142508 | 0.72 | DRD3 (0.58) | DRD3DRD2 | |
| SCHEMBL17980257 | 0.70 | UCHL1 (0.45) | HSD11B1 | |
| SCHEMBL28454230 | 0.70 | UCHL1 (0.45) | HSD11B1 | |
| Maleic Acid SCHEMBL11200074 | 0.70 | DRD3 (0.49) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | DRD3 955/4885HSD11B1 2203/4885DRD2 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.